Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP324397.RAwK6wRsMOJAydf-Q8fpUptR-VMtdk-15cUf2xOs3X_J0130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP324397.RAwK6wRsMOJAydf-Q8fpUptR-VMtdk-15cUf2xOs3X_J0130_assertion type Assertion NP324397.RAwK6wRsMOJAydf-Q8fpUptR-VMtdk-15cUf2xOs3X_J0130_head.
- NP324397.RAwK6wRsMOJAydf-Q8fpUptR-VMtdk-15cUf2xOs3X_J0130_assertion wasGeneratedBy ECO_0000203 NP324397.RAwK6wRsMOJAydf-Q8fpUptR-VMtdk-15cUf2xOs3X_J0130_provenance.
- NP324397.RAwK6wRsMOJAydf-Q8fpUptR-VMtdk-15cUf2xOs3X_J0130_assertion wasDerivedFrom befree-20150227 NP324397.RAwK6wRsMOJAydf-Q8fpUptR-VMtdk-15cUf2xOs3X_J0130_provenance.
- NP324397.RAwK6wRsMOJAydf-Q8fpUptR-VMtdk-15cUf2xOs3X_J0130_assertion SIO_000772 12615701 NP324397.RAwK6wRsMOJAydf-Q8fpUptR-VMtdk-15cUf2xOs3X_J0130_provenance.
- NP324397.RAwK6wRsMOJAydf-Q8fpUptR-VMtdk-15cUf2xOs3X_J0130_assertion evidence source_evidence_literature NP324397.RAwK6wRsMOJAydf-Q8fpUptR-VMtdk-15cUf2xOs3X_J0130_provenance.
- NP324397.RAwK6wRsMOJAydf-Q8fpUptR-VMtdk-15cUf2xOs3X_J0130_assertion description "[Clinical studies testing the efficacy of COX inhibition as adjuvant therapy for ovarian cancer may see more beneficial effects with adjuvant therapy with either a COX-1 selective or nonselective cyclooxygenase inhibitor as compared with a COX-2 selective drug.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP324397.RAwK6wRsMOJAydf-Q8fpUptR-VMtdk-15cUf2xOs3X_J0130_provenance.